SCHEMBL20045099

SCHEMBL20045099

CCc1c(C)cccc1CC(=O)OC

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 3/20 0.44
KDM4E B2RXH2 1/20 0.43
PTGS2 P35354 2/20 0.42
SHBG P04278 1/20 0.40
LMNA P02545 1/20 0.39
GABRA1 P14867 1/20 0.38
GABRB2 P47870 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TP53 P04637 1/20 0.38
CYP3A4 P08684 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2687097 0.82 EGFR (0.45) NLRP3KDM4ELMNASMN1; SMN2HSD17B10
SCHEMBL31619461 0.82 SMN1; SMN2 (0.49) NLRP3KDM4ELMNASMN1; SMN2ALDH1A1
SCHEMBL31619490 0.82 SMN1; SMN2 (0.49) NLRP3KDM4ELMNASMN1; SMN2ALDH1A1
SCHEMBL728665 0.81 KDM4E (0.49) NLRP3KDM4EPTGS2LMNASMN1; SMN2
SCHEMBL14420088 0.81 NLRP3 (0.47) NLRP3KDM4EPTGS2GABRA1GABRB2
SCHEMBL20045094 0.81 PTGS2 (0.56) KDM4EPTGS2SHBGGABRA1GABRB2
SCHEMBL265432 0.80 CTBP2 (0.51) KDM4ESHBGLMNAALDH1A1
SCHEMBL30522283 0.80 CTBP2 (0.51) KDM4ESHBGLMNAALDH1A1
SCHEMBL9883943 0.80 EGFR (0.47) NLRP3KDM4EGABRA1GABRB2ALDH1A1
SCHEMBL18514426 0.80 SLC22A12 (0.46) NLRP3KDM4EPTGS2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180098952-A1 INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA NORTHWESTERN UNIVERSITY (US) 2018-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180098952-A1 INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA OAT, OTC, ABAT NLRP3 2699/4885KDM4E 2714/4885PTGS2 1138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.